FirstWord Analyst Notes: Prostate Cancer and PARP inhibitors - YouTube
Frontiers | PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
PARP in Combination with Standard-of-Care Treatment
Clinical trials of PARP inhibitors in prostate cancer with defects in... | Download Scientific Diagram
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence - Cancer Treatment Reviews
PARP inhibition in breast cancer: progress made and future hopes | npj Breast Cancer
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors - European Urology
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
DNA Damage Repair Deficiency in Prostate Cancer: Trends in Cancer
Podcast Pearls: Prostate Cancer PARPi - Podcast - PARP Combinations in Prostate Cancer - Oncology - Clinical Care Options
ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy?
PARPi in Advanced PCa - Downloadable Slidesets - PARPi in Prostate Cancer - Oncology - Clinical Care Options
Researchers Identify Promising New Drug Target for Metastatic Prostate Cancer - Brigham On a Mission
AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
